FIBRYGA
Biological
Octapharma USA, Inc.
Total Payments
$418,333
Transactions
461
Doctors
234
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $117,905 | 102 | 96 |
| 2023 | $104,586 | 84 | 20 |
| 2022 | $29,338 | 40 | 22 |
| 2021 | $97,160 | 39 | 30 |
| 2020 | $49,219 | 98 | 17 |
| 2019 | $8,582 | 92 | 72 |
| 2017 | $11,543 | 6 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $155,593 | 15 | 37.2% |
| Honoraria | $126,000 | 48 | 30.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $73,449 | 3 | 17.6% |
| Grant | $30,000 | 1 | 7.2% |
| Travel and Lodging | $18,634 | 94 | 4.5% |
| Food and Beverage | $12,672 | 289 | 3.0% |
| Consulting Fee | $1,756 | 8 | 0.4% |
| Education | $230.00 | 3 | 0.1% |
Payments by Type
General
$262,740
446 transactions
Research
$155,593
15 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Fibryga in pediatric cardiac surgery patients | Octapharma USA, Inc. | $46,414 | 0 |
| Fibryga in ECMO patients | Octapharma USA, Inc. | $32,025 | 0 |
| A Pilot and Feasibility Study Comparing Fibrinogen Concentrate and Cryoprecipitate in Children | Octapharma USA, Inc. | $23,890 | 0 |
| Acquired hypofibrinogenemia in acute leukemia - retrospective data collection | Octapharma USA, Inc. | $19,000 | 0 |
| Real-World Evidence with a Human Fibrinogen Concentrate (Fibryga) for the Management of Fibrinogen Deficiency in the U.S. | Octapharma USA, Inc. | $15,884 | 0 |
| Forma-02 | Octapharma USA, Inc. | $11,380 | 0 |
| Fiirst-2 | Octapharma USA, Inc. | $7,000 | 2 |
Top Doctors Receiving Payments for FIBRYGA — Page 9
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Medical Oncology | Santa Rosa Beach, FL | $16.99 | 1 |
| , MD | Obstetrics & Gynecology | Monroeville, PA | $16.71 | 1 |
| , M.D | Obstetrics & Gynecology | Monroeville, PA | $16.71 | 1 |
| , MD | Hematology & Oncology | West Orange, NJ | $15.45 | 1 |
| , D.O | Hematology & Oncology | Newark, NJ | $15.45 | 1 |
| , MD | Internal Medicine | Paterson, NJ | $15.45 | 1 |
| , M.D | Hematology & Oncology | Newark, NJ | $15.45 | 1 |
| , MD | Hematology & Oncology | Newark, NJ | $15.45 | 1 |
| Balraj Singh | Hematology & Oncology | Paterson, NJ | $15.45 | 1 |
| , M.D | Radiation Oncology | Saddle Brook, NJ | $15.45 | 1 |
| , DO | Anatomic Pathology & Clinical Pathology | Burlington, CT | $14.91 | 1 |
| , M.D | Gynecologic Oncology | Weirton, WV | $14.42 | 1 |
| , M.D | Obstetrics & Gynecology | Weirton, WV | $14.42 | 1 |
| , PA-C | Medical | Weirton, WV | $14.42 | 1 |
| , MD | Obstetrics & Gynecology | Weirton, WV | $14.42 | 1 |
| , M.D | Internal Medicine | Orlando, FL | $14.35 | 1 |
| , CRNA | Registered Nurse | Chattanooga, TN | $13.35 | 1 |
| , MD | Anesthesiology | Chattanooga, TN | $13.35 | 1 |
| Julie Gallant | Critical Care Medicine | Ringgold, GA | $13.35 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Chattanooga, TN | $13.35 | 1 |
| , MD | Anesthesiology | Chattanooga, TN | $13.35 | 1 |
| , RN | Critical Care Medicine | Chattanooga, TN | $13.35 | 1 |
| , CRNA | Registered Nurse | Chattanooga, TN | $13.35 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Chattanooga, TN | $13.35 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Chattanooga, TN | $13.35 | 1 |
Ad
Manufacturing Companies
- Octapharma USA, Inc. $418,333
Product Information
- Type Biological
- Total Payments $418,333
- Total Doctors 234
- Transactions 461
About FIBRYGA
FIBRYGA is a biological associated with $418,333 in payments to 234 healthcare providers, recorded across 461 transactions in the CMS Open Payments database. The primary manufacturer is Octapharma USA, Inc..
Payment data is available from 2017 to 2024. In 2024, $117,905 was paid across 102 transactions to 96 doctors.
The most common payment nature for FIBRYGA is "Unspecified" ($155,593, 37.2% of total).
FIBRYGA is associated with 7 research studies, including "Fibryga in pediatric cardiac surgery patients" ($46,414).